Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Immunophotonics, Inc.
Modality
UNKNOWN
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07321847CT.gov Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ip-001 (this asset) | Immunophotonics, Inc. | P2/3 | B · 57 |
| Irinotecan | Sun Yat-sen University | P4 | BBB |
| Fluorouracilum | Seoul National University Hospital | P3 | BBB |
| Oxaliplatin | Sun Yat-sen University | P3 | BBB |
| Capecitabine | Tao Zhang | P3 | BB |
| Indocyanine Green | National Cancer Center, China | P3 | BB |
| Cetuximab | Fudan University | P3 | BB |
| Tipiracil | Academic and Community Cancer Research United | P2 | BB |
| Trifluridine | Academic and Community Cancer Research United | P2 | BB |
+42 more in the Rectal Cancer cohort
Other indications for ip-001
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastasis From Malignant Tumor Of Colon | — | P2/3 | BB · 64 |
| Colorectal Cancer | — | P2/3 | CCC · 52 |
| Rectal Carcinoma | — | P2/3 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ip-001 in Rectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/ip-001-rectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →